LDI has sold UltiMed to Levine Leichtman Capital Partners

UltiMed, Inc., a portfolio company of LDI, Ltd., has been sold to an investment vehicle sub-managed by Levine Leichtman Capital Partners, LLC.

UltiMed’s insulin pen needles, syringes and complementary products are critical offerings for diabetes patients who need daily insulin injections and for companion animals who increasingly suffer from this life-threatening disease. UltiMed’s proprietary “dispense and dispose” solutions provide diabetes patients a safe and convenient way to store used sharps following injection.

Levine Leichtman Capital Partners is a private equity and venture capital firm specializing in acquisitions, buyouts, recapitalizations, refinancing, balance sheet restructuring, growth financing, structured equity, distressed debt, leveraged loan and mezzanine investments in the middle market.

LDI, Ltd. is a private equity firm specializing in investing in acquisitions and add-on acquisitions. It is a family office based in Indianapolis, IN, with more than a century of experience funding and operating high-potential, middle-market companies.

One of Oaklins’ teams in the USA served as the exclusive financial advisor to UltiMed, Inc., a portfolio company of LDI, Ltd., in this transaction.

Service

M&A sell-side

Parties

“We selected the team based on their prior experience with UltiMed and their expertise in transactions in the diabetes and animal health sectors. They did an outstanding job of presenting UltiMed’s many strengths and growth opportunities to the market, and their deep relationships with potential acquirors were key to our success. We particularly appreciate the senior team focus they brought to completing this transaction despite the emergence of the COVID-19 pandemic in the midst of this assignment.”

John Martin

VP Corporate Development, LDI, Ltd.

Talk to the deal team

Michael S. Goldman

Managing Director

New York, United States
Oaklins TM Capital

View profile Get in touch

Steve Hunter

Managing Director

Atlanta, United States
Oaklins TM Capital

View profile Get in touch

James McLaren

Managing Director

New York, United States
Oaklins TM Capital

View profile Get in touch

John Dean

Associate Director

Atlanta, United States
Oaklins TM Capital

View profile Get in touch

Related deals

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

Private Equity | Construction & Engineering Services | Energy | TMT

iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets

iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.

Learn more

Chequers Capital has acquired Gourmet Italian Food to strengthen presence in the ready meals sector

Private Equity | Food & Beverage

Chequers Capital has acquired Gourmet Italian Food to strengthen presence in the ready meals sector

Chequers Partenaires S.A., acting as the management company of the private equity fund Chequers Capital XVIII SLP, together with management, has completed the acquisition of 100% of the share capital of Gourmet Italian Food S.p.A. (GIF). The company was previously owned by Alcedo SGR S.p.A. through the Alcedo IV Fund, FVS SGR S.p.A. through the Sviluppo PMI Fund, and minority shareholders.

Learn more

Pharma-Skan & Skan-Medic have been acquired by Brygge Partners

Healthcare

Pharma-Skan & Skan-Medic have been acquired by Brygge Partners

Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.

Learn more